AHAlison Hiong

Alison Hiong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alison Hiong has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Treatment Timeliness in Extensive-Stage SCLC and Impact on Survival: A Registry-Based Observational Study

    by Alison Hiong, Julien Robinson, Eldho Paul, Sanuki Tissera, Jessie Zeng, Craig Underhill, Sagun Parakh, Louis Irving, Wasek Faisal, Rob Blum, et al.

  • Uveal Melanoma Treatment: An Update

    by Alison Hiong, Darvy Dang, Malaka Ameratunga, Roderick O'DAy

    Uveal melanoma is a rare malignancy arising from uveal tract melanocytes. Definitive treatment options for primary disease include plaque brachytherapy, proton beam radiotherapy and enucleation, which provide high rates of local control, but are associated with vision impairment, reduced quality of life and unsatisfactorily high rates of metastatic relapse. In the metastatic setting, average life expectancy remains less than 2 years, despite the availability of immune checkpoint inhibitors and the more recent arrival of the T cell‐engaging agent, tebentafusp. Here, we provide an update regarding the current treatment of uveal melanoma, and discuss the potential roles of novel targeted therapies, immunotherapy and neoadjuvant therapy in shaping future management.


  • Open Access

    Perioperative chemotherapy use and related outcomes in muscle‐invasive bladder cancer in Australia

    by Alison Hiong, James Lynam, Andrew Weickhardt, Shirley Wong, Shomik Sengupta, Paul Manohar, Lih‐Ming Wong, Philip Dundee, Nathan Lawrentschuk, Alison Y. Zhang, et al.

    Objectives: To explore Australian data on perioperative chemotherapy use and associated outcomes in muscle‐invasive bladder cancer (MIBC).Subjects and Methods: An observational study of patients with MIBC treated with neoadjuvant chemotherapy, adjuvant chemotherapy or surgery alone was conducted using data from BLADDA, a multicentre Australian urothelial cancer registry. Pathological response to neoadjuvant chemotherapy and its effect on event‐free survival (EFS) and overall survival (OS) were determined. EFS and OS in patients who underwent neoadjuvant chemotherapy, adjuvant chemotherapy or surgery alone were compared using univariate and multivariable proportional hazards regression.Results: From 2018 to 2024, 259 patients enrolled in the BLADDA registry met inclusion criteria, of which 45% received neoadjuvant chemotherapy, 23% received adjuvant chemotherapy, 1.2% received both neoadjuvant and adjuvant chemotherapy and 31% underwent surgery only. The proportion of patients treated with neoadjuvant chemotherapy increased over time. A total of 21 of 67 (31%) evaluable subjects achieved a pathological complete response, which was associated with improved EFS and OS. Excluding patients who received both neoadjuvant and adjuvant chemotherapy, the EFS hazard ratio (HR) was 0.43 (95% confidence interval [CI] 0.29–0.65, p < 0.001) for neoadjuvant chemotherapy and 0.59 (95% CI 0.38–0.94, p = 0.03) for adjuvant chemotherapy compared to surgery alone. Neoadjuvant chemotherapy was associated with prolonged OS in the univariate analysis (HR 0.43, 95% CI 0.26–0.73, p = 0.002) but not in the multivariable analysis (HR 0.59, 95% CI 0.32–1.08, p = 0.09). OS was not improved with adjuvant chemotherapy (unadjusted HR 0.76, 95% CI 0.44–1.31, p = 0.3; adjusted HR 0.86, 95% CI 0.46–1.60, p = 0.6).Conclusion: Neoadjuvant chemotherapy use for MIBC in Australia has increased over the past decade, but it remains underutilised. This has important implications as perioperative chemo‐immunotherapy emerges as a standard of care. Although a clear impact on survival in the overall population was not observed, this was potentially due to the limited sample size.


  • Herpes zoster in patients with glioma treated with temozolomide

    by Alison Hiong, Adam H. Lapidus, Lucy Gately, Grace Sinclair, Malaka Ameratunga


  • Globe Salvage and Vision Preservation by Neoadjuvant Darovasertib and Crizotinib in Uveal Melanoma

    by Alison Hiong, Roderick O’dAy, Lotte S. Fog, Daniel McKay, John McKenzie, Malaka Ameratunga, Anthony M. Joshua, Mark Shackleton


  • Sepsis following cancer surgery: the need for early recognition and standardised clinical care

    by A. Hiong, K. A. Thursky, B. W. Teh, G. M. Haeusler, M. A. Slavin, L. J. Worth

    Despite the implementation of multimodal bundles of care in hospitalised patients, post-operative sepsis in patients with cancer still accounts for a significant burden of illness and substantial healthcare costs. Patients undergoing surgery for cancer are at particular risk of sepsis due to underlying malignancy, being immunocompromised associated with cancer management and the complexity of surgical procedures performed. In this review, we evaluate the burden of illness and risks for sepsis following surgery for cancer. Current evidence supporting standardised strategies for sepsis management (including early recognition and resuscitation) is examined together with challenges in implementing quality improvement programs.